Jefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Sciences, and Piramal Pharma for gains up to 30%, while flagging Laurus Labs as underperforming.